Simplify Logo

Full-Time

Senior Manager

Regulatory Affairs

Posted on 6/27/2024

Cytokinetics

Cytokinetics

201-500 employees

Develops drugs for muscle function improvement

Hardware
Biotechnology
Healthcare

Compensation Overview

$165k - $175kAnnually

Senior

Remote in USA

Category
Public Health
Biology & Biotech
Requirements
  • Bachelor’s degree in a scientific field
  • 8+ years of drug development experience
  • 5+ years of regulatory affairs experience in Biotech/Pharmaceutical industry
  • Experience in small molecule drug development
  • Experience in cardiovascular therapeutic area is a plus
  • Knowledge of international regulatory requirements
  • Experience with eCTD requirements and electronic submissions
  • Excellent communication and organizational skills
Responsibilities
  • Formulate regulatory strategies based on current regulatory intelligence
  • Collaborate with project teams and external partners to develop regulatory strategies
  • Manage preparation and submission of regulatory documents
  • Review global regulatory submissions for consistency
  • Prepare responses to queries from regulatory authorities
  • Maintain knowledge of FDA/EMA regulations and guidelines
  • Provide regulatory advice to other functional areas
  • Participate in regulatory due diligence activities
  • Build relationships with external partners and regulatory authorities
  • Supervise employees in Regulatory Affairs
  • Develop and implement regulatory operating guidelines

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$1.2B

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

0%

1 year growth

1%

2 year growth

21%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.
INACTIVE